B+
Bull case
30%
Probability
Target price
$24.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
SMMT
Summit TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The April 30 company update kept the core ivonescimab timeline intact: ASCO OS data on May 31, HARMONi-3 squamous final PFS still in 2H 2026, and the November 14, 2026 PDUFA unchanged. The interim HARMONi-3 review did not raise safety concerns, which preserves the lead-program thesis [#8-K-2026-04-30].
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -5.4.
What can break
Lead-asset concentration remains extreme; ivonescimab drives the thesis, so weak ASCO, Phase III, or FDA outcomes could re-rate the equity sharply lower.
Momentum
79
Value
41
Sentiment
60
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $15.00 · Bull $24.00 · Bear $9.00Analysis 2026-05-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $30.06
Why
Momentum79 · Δ7d +2.0
Value41 · Δ7d -0.1
Sentiment60 · Δ7d -5.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -5.4.
Contradictions & invalidation
- • Lead-asset concentration remains extreme; ivonescimab drives the thesis, so weak ASCO, Phase III, or FDA outcomes could re-rate the equity sharply lower.
- • Program breadth is expanding across multiple trials and collaborations, which raises execution complexity, enrollment risk, and spending needs before any U.S. approval-derived revenue arrives.
- • The same update also showed the interim HARMONi-3 look was not the breakthrough event some investors may have wanted, with the study simply continuing as planned.
Catalyst clock
2026-05-31
ASCO plenary overall-survival data from HARMONi-6
Lead driver: Sentiment · See AI snapshot
Momentum
79
8% active weight
Current posture
7d trendFlat
Δ7d
+2.0
Δ21d
-7.6
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
60
45% active weight
Current posture
7d trendSoftening
Δ7d
-5.4
Δ21d
+0.1
Why this grade
Composite grade C. Momentum 78.8 / Value 40.6 / Sentiment 60.4
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-04. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$15.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-05-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$12.37B
Beta
-1.44
Shares Out
797.75M
P/E (TTM) · Derived
-10.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-25.96
Rev YoY
-100.0%
EPS YoY
-63.6%
Gross Margin
+97.2%
Op Margin
-
Net Debt
-$692.87M
Current Ratio
6.96
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data